gdc-0449 and Ear-Neoplasms

Basal cell carcinoma (BCC), the most common cancer in the U.S.A., is treated primarily with local excision. In some cases, lesion size, location or extent prevent complete resection. Locally advanced BCC responds to systemic therapy with the Hedgehog pathway inhibitor vismodegib, but withdrawal of treatment may result in disease relapse. Here we present a case of locally advanced auricular BCC treated with induction vismodegib and radiation, resulting in durable local control and an acceptable level of acute toxicity.

Topics: Anilides; Antineoplastic Agents; Carcinoma, Basal Cell; Combined Modality Therapy; Ear Neoplasms; Hedgehog Proteins; Humans; Male; Middle Aged; Pyridines; Skin Neoplasms

Topics: Aged; Anilides; Antineoplastic Agents; Basal Cell Nevus Syndrome; Ear Neoplasms; Female; Humans; Male; Middle Aged; Orbital Neoplasms; Pyridines